CLAIMS


What is claimed is:

5 1. Use of a compound in the manufacture of a medicament for the treatment of inflammatory bowel disease, said compound comprising

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group; A is −(CH₂)₆-, cis −CH₂CH=CH-(CH₂)₃-, or −CH₂C≡C-(CH₂)₃-, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is −(CH₂)_m-Ar-(CH₂)_o- wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH₂ may be substituted with S or O; and D is aryl or heteroaryl.

- 15 2. Use of claim 1 wherein D in said compound is phenyl.
 - 3. Use of claim 2 wherein D in said compound is chlorophenyl.
 - 4. Use of claim 3 wherein D in said compound is 3,5-dichlorophenyl.
 - 5. Use of claim 2 wherein D in said compound is unsubstituted phenyl.
 - 6. Use of claim 1 wherein A in said compound is -(CH₂)₆-, cis -CH₂CH=CH-(CH₂)₃-, or -CH₂C≡C-(CH₂)₃-.
- 20 7. Use of claim 2, said compound comprising



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein R³ is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH₂, OH, CN, NO₂, or CF₃; and

- 25 n is 0, 1, 2, or 3.
 - 8. Use of claim 7, said compound comprising

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein a dashed line indicates the presence or absence of a covalent bond.

9. Use of claim 2, said compound comprising

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein R^3 is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH_2 , OH, CN, NO_2 , or CF_3 ;

 R^4 is hydroxyhydrocarbyl having from 1 to 10 carbon atoms; and n is 0, 1, 2, or 3.

10. A compound comprising

5

10

or a pharmaceutically acceptable salt or a prodrug thereof.

WO 2006/121708 PCT/US2006/016804

AMENDED CLAIMS

Received by the International Bureau on 03 October 2006 (03.10.2006)

What is claimed is:

1. A compound of the formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;

wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;

A is $-(CH_2)_6$ -, cis $-CH_2CH=CH-(CH_2)_3$ -, or $-CH_2C\equiv C-(CH_2)_3$ -, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is $-(CH_2)_m$ -Ar- $-(CH_2)_0$ - wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH_2 may be substituted with S or O; and D is aryl or heteroaryl.

- 2. The compound of claim 1 wherein D is phenyl.
- 3. The compound of claim 2 wherein D is chlorophenyl.
- 4. The compound of claim 3 wherein D is 3,5-dichlorophenyl.
- 5. The compound of claim 2 wherein D is unsubstituted phenyl.
- 6. The compound according to any one of claims 1 to 5, wherein A is $-(CH_2)_6$ -, cis $-CH_2CH=CH-(CH_2)_3$ -, or $-CH_2C\equiv C-(CH_2)_3$ -.
- 7. The compound of claim 2 having the formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein \mathbb{R}^3 is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH₂, OH, CN, NO₂, or CF₃; and n is 0, 1, 2, or 3.

8. The compound of claim 7 having the formula

WO 2006/121708 PCT/US2006/016804

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein a dashed line indicates the presence or absence of a covalent bond.

9. The compound of claim 2 having the formula

or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein R³ is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH₂, OH, CN, NO₂, or CF₃;

 R^4 is hydroxyhydrocarbyl having from 1 to 10 carbon atoms; and n is 0, 1, 2, or 3.

10. The compound of claim 9 having the formula

or a pharmaceutically acceptable salt or a prodrug thereof.

- 11. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prevention of glaucoma or ocular hypertension.
- 12. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prevention of for the treatment of inflammatory bowel disease.

13. A liquid comprising a compound according to any one of claims 1 to 10, wherein said liquid is ophthalmically acceptable.